Histone deacetylase inhibitors suppress TF-κB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes

Jianguo Wang, Shawn A. Mahmud, Peter B. Bitterman, Yuqing Huo, Arne Slungaard

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Histone deacetylase inhibitors (HDACi), such as trichostatin A (TSA), can regulate gene expression by promoting acetylation of histones and transcription factors. Human tissue factor (TF) expression is partly governed by a unique, NF-κB-related "TF-κB" promoter binding site. We find that TSA and four other HDACi (apicidin, MS-275, sodium butyrate, and valproic acid) all inhibit by ∼90% TF activity and protein level induction in human umbilical vein endothelial cells stimulated by the physiologic agonists tumor necrosis factor (TNF)-α, interleukin-1β, lipopolysaccharide, and HOSCN without affecting expression of the NF-κB-regulated adhesion molecules ICAM-1 and E-selectin. TSA and butyrate also blunt TF induction ∼50% in vitro in peripheral blood mononuclear cells and in vivo in thioglycolate-elicited murine peritoneal macrophages. In human umbilical vein endothelial cells, TSA attenuates by ∼70% TNF-α stimulation of TF mRNA transcription without affecting that of ICAM-1. By electrophoretic mobility shift assay analyses, TNF-α and lipopolysaccharide induce strong p65/p50 and p65/ c-Rel heterodimer binding to both NF-κB and TF-κB probes. TSA nearly abolishes TF-κB binding without affecting NF-κB binding. A chromatin immunoprecipitation assay and a promoter-luciferase reporter system confirm that TSA inhibits TF-κB but not NF-κB activation. Chromatin immunoprecipitation and small interfering RNA inhibitor studies demonstrate that HDAC3 plays a significant role in TNF-α-mediated TF induction. Thus, HDACi transcriptionally inhibit agonist-induced TF expression in endothelial cells and monocytes by a TF-αB- and HDAC3-dependent mechanism. We conclude that histone deacetylases, particularly HDAC3, play a hitherto unsuspected role in regulating TF expression and raise the possibility that HDACi might be a novel therapy for thrombotic disorders.

Original languageEnglish (US)
Pages (from-to)28408-28418
Number of pages11
JournalJournal of Biological Chemistry
Volume282
Issue number39
DOIs
StatePublished - Sep 28 2007

Fingerprint

Histone Deacetylase Inhibitors
Endothelial cells
Thromboplastin
Monocytes
trichostatin A
Endothelial Cells
Tumor Necrosis Factor-alpha
Chromatin Immunoprecipitation
Human Umbilical Vein Endothelial Cells
Intercellular Adhesion Molecule-1
Chromatin
Lipopolysaccharides
Assays
Thioglycolates
Acetylation
Electrophoretic mobility
E-Selectin
Histone Deacetylases
Butyric Acid
Butyrates

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Histone deacetylase inhibitors suppress TF-κB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. / Wang, Jianguo; Mahmud, Shawn A.; Bitterman, Peter B.; Huo, Yuqing; Slungaard, Arne.

In: Journal of Biological Chemistry, Vol. 282, No. 39, 28.09.2007, p. 28408-28418.

Research output: Contribution to journalArticle

Wang, Jianguo ; Mahmud, Shawn A. ; Bitterman, Peter B. ; Huo, Yuqing ; Slungaard, Arne. / Histone deacetylase inhibitors suppress TF-κB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. In: Journal of Biological Chemistry. 2007 ; Vol. 282, No. 39. pp. 28408-28418.
@article{e7581d6596674768a1c70f9273fc6221,
title = "Histone deacetylase inhibitors suppress TF-κB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes",
abstract = "Histone deacetylase inhibitors (HDACi), such as trichostatin A (TSA), can regulate gene expression by promoting acetylation of histones and transcription factors. Human tissue factor (TF) expression is partly governed by a unique, NF-κB-related {"}TF-κB{"} promoter binding site. We find that TSA and four other HDACi (apicidin, MS-275, sodium butyrate, and valproic acid) all inhibit by ∼90{\%} TF activity and protein level induction in human umbilical vein endothelial cells stimulated by the physiologic agonists tumor necrosis factor (TNF)-α, interleukin-1β, lipopolysaccharide, and HOSCN without affecting expression of the NF-κB-regulated adhesion molecules ICAM-1 and E-selectin. TSA and butyrate also blunt TF induction ∼50{\%} in vitro in peripheral blood mononuclear cells and in vivo in thioglycolate-elicited murine peritoneal macrophages. In human umbilical vein endothelial cells, TSA attenuates by ∼70{\%} TNF-α stimulation of TF mRNA transcription without affecting that of ICAM-1. By electrophoretic mobility shift assay analyses, TNF-α and lipopolysaccharide induce strong p65/p50 and p65/ c-Rel heterodimer binding to both NF-κB and TF-κB probes. TSA nearly abolishes TF-κB binding without affecting NF-κB binding. A chromatin immunoprecipitation assay and a promoter-luciferase reporter system confirm that TSA inhibits TF-κB but not NF-κB activation. Chromatin immunoprecipitation and small interfering RNA inhibitor studies demonstrate that HDAC3 plays a significant role in TNF-α-mediated TF induction. Thus, HDACi transcriptionally inhibit agonist-induced TF expression in endothelial cells and monocytes by a TF-αB- and HDAC3-dependent mechanism. We conclude that histone deacetylases, particularly HDAC3, play a hitherto unsuspected role in regulating TF expression and raise the possibility that HDACi might be a novel therapy for thrombotic disorders.",
author = "Jianguo Wang and Mahmud, {Shawn A.} and Bitterman, {Peter B.} and Yuqing Huo and Arne Slungaard",
year = "2007",
month = "9",
day = "28",
doi = "10.1074/jbc.M703586200",
language = "English (US)",
volume = "282",
pages = "28408--28418",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "39",

}

TY - JOUR

T1 - Histone deacetylase inhibitors suppress TF-κB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes

AU - Wang, Jianguo

AU - Mahmud, Shawn A.

AU - Bitterman, Peter B.

AU - Huo, Yuqing

AU - Slungaard, Arne

PY - 2007/9/28

Y1 - 2007/9/28

N2 - Histone deacetylase inhibitors (HDACi), such as trichostatin A (TSA), can regulate gene expression by promoting acetylation of histones and transcription factors. Human tissue factor (TF) expression is partly governed by a unique, NF-κB-related "TF-κB" promoter binding site. We find that TSA and four other HDACi (apicidin, MS-275, sodium butyrate, and valproic acid) all inhibit by ∼90% TF activity and protein level induction in human umbilical vein endothelial cells stimulated by the physiologic agonists tumor necrosis factor (TNF)-α, interleukin-1β, lipopolysaccharide, and HOSCN without affecting expression of the NF-κB-regulated adhesion molecules ICAM-1 and E-selectin. TSA and butyrate also blunt TF induction ∼50% in vitro in peripheral blood mononuclear cells and in vivo in thioglycolate-elicited murine peritoneal macrophages. In human umbilical vein endothelial cells, TSA attenuates by ∼70% TNF-α stimulation of TF mRNA transcription without affecting that of ICAM-1. By electrophoretic mobility shift assay analyses, TNF-α and lipopolysaccharide induce strong p65/p50 and p65/ c-Rel heterodimer binding to both NF-κB and TF-κB probes. TSA nearly abolishes TF-κB binding without affecting NF-κB binding. A chromatin immunoprecipitation assay and a promoter-luciferase reporter system confirm that TSA inhibits TF-κB but not NF-κB activation. Chromatin immunoprecipitation and small interfering RNA inhibitor studies demonstrate that HDAC3 plays a significant role in TNF-α-mediated TF induction. Thus, HDACi transcriptionally inhibit agonist-induced TF expression in endothelial cells and monocytes by a TF-αB- and HDAC3-dependent mechanism. We conclude that histone deacetylases, particularly HDAC3, play a hitherto unsuspected role in regulating TF expression and raise the possibility that HDACi might be a novel therapy for thrombotic disorders.

AB - Histone deacetylase inhibitors (HDACi), such as trichostatin A (TSA), can regulate gene expression by promoting acetylation of histones and transcription factors. Human tissue factor (TF) expression is partly governed by a unique, NF-κB-related "TF-κB" promoter binding site. We find that TSA and four other HDACi (apicidin, MS-275, sodium butyrate, and valproic acid) all inhibit by ∼90% TF activity and protein level induction in human umbilical vein endothelial cells stimulated by the physiologic agonists tumor necrosis factor (TNF)-α, interleukin-1β, lipopolysaccharide, and HOSCN without affecting expression of the NF-κB-regulated adhesion molecules ICAM-1 and E-selectin. TSA and butyrate also blunt TF induction ∼50% in vitro in peripheral blood mononuclear cells and in vivo in thioglycolate-elicited murine peritoneal macrophages. In human umbilical vein endothelial cells, TSA attenuates by ∼70% TNF-α stimulation of TF mRNA transcription without affecting that of ICAM-1. By electrophoretic mobility shift assay analyses, TNF-α and lipopolysaccharide induce strong p65/p50 and p65/ c-Rel heterodimer binding to both NF-κB and TF-κB probes. TSA nearly abolishes TF-κB binding without affecting NF-κB binding. A chromatin immunoprecipitation assay and a promoter-luciferase reporter system confirm that TSA inhibits TF-κB but not NF-κB activation. Chromatin immunoprecipitation and small interfering RNA inhibitor studies demonstrate that HDAC3 plays a significant role in TNF-α-mediated TF induction. Thus, HDACi transcriptionally inhibit agonist-induced TF expression in endothelial cells and monocytes by a TF-αB- and HDAC3-dependent mechanism. We conclude that histone deacetylases, particularly HDAC3, play a hitherto unsuspected role in regulating TF expression and raise the possibility that HDACi might be a novel therapy for thrombotic disorders.

UR - http://www.scopus.com/inward/record.url?scp=35348974994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348974994&partnerID=8YFLogxK

U2 - 10.1074/jbc.M703586200

DO - 10.1074/jbc.M703586200

M3 - Article

VL - 282

SP - 28408

EP - 28418

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 39

ER -